Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $85.11 USD
Change Today -1.88 / -2.16%
Volume 1.9M
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Minerva House

Simmonscourt Road

Ballsbridge

Dublin, 4

Ireland

Phone: 353 1 268 2000

Fax:

Endo International plc operates as a specialty healthcare company focused on branded and generic pharmaceuticals and devices worldwide. The company’s major subsidiary in the United States is Endo Health Solutions Inc. Segments The company operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. U.S. Branded Pharmaceuticals This segment includes various branded prescription products related to treating and managing pain, as well as the company’s urology, endocrinology and oncology products. The marketed products that are included in this segment include Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto. Lidoderm: A topical patch product containing lidocaine, Lidoderm is the first FDA (the U.S. Food and Drug Administration)-approved product for the relief of the pain associated with post-herpetic neuralgia, a condition thought to result after nerve fibers are damaged during a case of Herpes Zoster (commonly known as shingles). In 2014, the company's U.S. Generic Pharmaceuticals segment launched its authorized generic of Lidoderm. Opana ER: Opana ER is an opioid agonist indicated for the management of pain severe enough to require daily, long-term opioid treatment and for which alternative treatment options are inadequate. Opana ER represents the first drug in which oxymorphone is available in an oral, extended-release formulation and is available in 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 40 mg tablets. The FDA approved a new formulation of Opana ER with INTAC technology. Voltaren Gel: The company launched Voltaren Gel upon closing of the license and supply agreement with Novartis AG and Novartis Consumer Health, Inc. Voltaren Gel received regulatory approval from the FDA, becoming the first topical prescription treatment for the relief of joint pain of osteoarthritis in the knees, ankles, feet, elbows, wrists, and hands; and became the first new product approved in the U.S. for osteoarthritis. Percocet: Percocet is approved for the treatment of moderate-to-moderately severe pain. Frova: The company began shipping Frova tablets upon closing of the license agreement with Vernalis Development Limited in 2004. Frova is indicated for the acute treatment of migraine headaches in adults. Fortesta Gel and Fortesta Gel Authorized Generic: Fortesta Gel is a patented 2% testosterone transdermal gel and is a treatment for men suffering from hypogonadism, also known as low testosterone (Low-T). The company has a license and supply agreement with Strakan International Limited, a subsidiary of ProStrakan Group plc (ProStrakan), for the right to commercialize Fortesta Gel in the U.S. Fortesta Gel is approved by the FDA. During 2014, the company announced that it had introduced the first and only generic 2% topical testosterone gel, an authorized generic of Fortesta Gel. Supprelin LA: Supprelin LA is a soft, flexible 12-month hydrogel implant based on the company’s hydrogel polymer technology that delivers histrelin acetate, a gonadotropin releasing hormone (GnRH) agonist and is indicated for the treatment of central precocious puberty in children. The company markets Supprelin LA in the U.S. through a specialty sales force primarily to pediatric endocrinologists. Valstar: Valstar is a sterile solution for intravesical instillation of valrubicin, a chemotherapeutic anthracycline derivative. Valstar is indicated for intravesical therapy of bacillus Calmette-Guerin-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Vantas: Vantas is a soft, flexible 12-month hydrogel implant based on the company’s hydrogel polymer technology that delivers histrelin acetate, a GnRH agonist; and is indicated for the palliative treatment of advanced prostate cancer. Sumavel DosePro: The company began shipping Sumavel DosePro upon closing of the product acquisition from Zogenix, Inc. in 2014. Sumavel DosePro is indicated for adults for the acute treatmen

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $85.11 USD -1.88

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.138.90 CHF -0.10
CR Bard Inc $196.29 USD +0.10
Edwards Lifesciences Corp $149.37 USD -1.72
Intuitive Surgical Inc $526.75 USD +0.25
Mallinckrodt PLC $106.73 USD -17.48
View Industry Companies
 

Industry Analysis

ENDP

Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.7x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit www.endo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.